These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 24090588)

  • 1. Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial.
    van der Vaart T; Plasschaert E; Rietman AB; Renard M; Oostenbrink R; Vogels A; de Wit MC; Descheemaeker MJ; Vergouwe Y; Catsman-Berrevoets CE; Legius E; Elgersma Y; Moll HA
    Lancet Neurol; 2013 Nov; 12(11):1076-83. PubMed ID: 24090588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioral and cognitive outcomes for clinical trials in children with neurofibromatosis type 1.
    van der Vaart T; Rietman AB; Plasschaert E; Legius E; Elgersma Y; Moll HA;
    Neurology; 2016 Jan; 86(2):154-60. PubMed ID: 26519538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.
    Krab LC; de Goede-Bolder A; Aarsen FK; Pluijm SM; Bouman MJ; van der Geest JN; Lequin M; Catsman CE; Arts WF; Kushner SA; Silva AJ; de Zeeuw CI; Moll HA; Elgersma Y
    JAMA; 2008 Jul; 300(3):287-94. PubMed ID: 18632543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA).
    Stivaros S; Garg S; Tziraki M; Cai Y; Thomas O; Mellor J; Morris AA; Jim C; Szumanska-Ryt K; Parkes LM; Haroon HA; Montaldi D; Webb N; Keane J; Castellanos FX; Silva AJ; Huson S; Williams S; Gareth Evans D; Emsley R; Green J;
    Mol Autism; 2018; 9():12. PubMed ID: 29484149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial.
    Chan D; Binks S; Nicholas JM; Frost C; Cardoso MJ; Ourselin S; Wilkie D; Nicholas R; Chataway J
    Lancet Neurol; 2017 Aug; 16(8):591-600. PubMed ID: 28600189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
    de Yebenes JG; Landwehrmeyer B; Squitieri F; Reilmann R; Rosser A; Barker RA; Saft C; Magnet MK; Sword A; Rembratt A; Tedroff J;
    Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study.
    Acosta MT; Kardel PG; Walsh KS; Rosenbaum KN; Gioia GA; Packer RJ
    Pediatr Neurol; 2011 Oct; 45(4):241-5. PubMed ID: 21907886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
    Sorensen PS; Lycke J; Erälinna JP; Edland A; Wu X; Frederiksen JL; Oturai A; Malmeström C; Stenager E; Sellebjerg F; Sondergaard HB;
    Lancet Neurol; 2011 Aug; 10(8):691-701. PubMed ID: 21742556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges of cognitive research in neurofibromatosis type 1.
    Acosta MT
    Lancet Neurol; 2013 Nov; 12(11):1040-1. PubMed ID: 24107290
    [No Abstract]   [Full Text] [Related]  

  • 10. Behavioural, academic and neuropsychological profile of normally gifted Neurofibromatosis type 1 children.
    Descheemaeker MJ; Ghesquière P; Symons H; Fryns JP; Legius E
    J Intellect Disabil Res; 2005 Jan; 49(Pt 1):33-46. PubMed ID: 15634310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychological profile in adults with neurofibromatosis type 1 compared to a control group.
    Descheemaeker MJ; Plasschaert E; Frijns JP; Legius E
    J Intellect Disabil Res; 2013 Sep; 57(9):874-86. PubMed ID: 23095048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
    Huntington Study Group Reach2HD Investigators
    Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study.
    Nseir W; Diab H; Mahamid M; Abu-Elheja O; Samara M; Abid A; Mograbi J
    Aliment Pharmacol Ther; 2012 Aug; 36(3):231-8. PubMed ID: 22646167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
    Chataway J; Schuerer N; Alsanousi A; Chan D; MacManus D; Hunter K; Anderson V; Bangham CR; Clegg S; Nielsen C; Fox NC; Wilkie D; Nicholas JM; Calder VL; Greenwood J; Frost C; Nicholas R
    Lancet; 2014 Jun; 383(9936):2213-21. PubMed ID: 24655729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial.
    Burns J; Ouvrier RA; Yiu EM; Joseph PD; Kornberg AJ; Fahey MC; Ryan MM
    Lancet Neurol; 2009 Jun; 8(6):537-44. PubMed ID: 19427269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial.
    Pride NA; Barton B; Hutchins P; Coghill DR; Korgaonkar MS; Hearps SJC; Rouel M; Malarbi S; North KN; Payne JM
    BMJ Open; 2018 Aug; 8(8):e021800. PubMed ID: 30166301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Pose E; Napoleone L; Amin A; Campion D; Jimenez C; Piano S; Roux O; Uschner FE; de Wit K; Zaccherini G; Alessandria C; Angeli P; Bernardi M; Beuers U; Caraceni P; Durand F; Mookerjee RP; Trebicka J; Vargas V; Andrade RJ; Carol M; Pich J; Ferrero J; Domenech G; Llopis M; Torres F; Kamath PS; Abraldes JG; Solà E; Ginès P
    Lancet Gastroenterol Hepatol; 2020 Jan; 5(1):31-41. PubMed ID: 31607677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
    Aarsland D; Ballard C; Walker Z; Bostrom F; Alves G; Kossakowski K; Leroi I; Pozo-Rodriguez F; Minthon L; Londos E
    Lancet Neurol; 2009 Jul; 8(7):613-8. PubMed ID: 19520613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive outcome in acute simvastatin treatment for aneurysmal subarachnoid hemorrhage: A propensity matched analysis.
    Wong GK; Wong A; Zee BC; Poon WS; Chan MT; Gin T; Siu DY; Mok VC
    J Neurol Sci; 2015 Nov; 358(1-2):58-61. PubMed ID: 26285662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.